Donzelli Sara, Mori Federica, Biagioni Francesca, Bellissimo Teresa, Pulito Claudio, Muti Paola, Strano Sabrina, Blandino Giovanni
Translational Oncogenomics Unit, Italian National Cancer Institute 'Regina Elena', Via Elio Chianesi 53, 00144 Rome, Italy.
Molecular Chemoprevention Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy.
Mol Cell Ther. 2014 Jun 1;2:16. doi: 10.1186/2052-8426-2-16. eCollection 2014.
Chemoresistance is one of the main problems in the therapy of cancer. There are a number of different molecular mechanisms through which a cancer cell acquires resistance to a specific treatment, such as alterations in drug uptake, drug metabolism and drug targets. There are several lines of evidence showing that miRNAs are involved in drug sensitivity of cancer cells in different tumor types and by different treatments. In this review, we provide an overview of the more recent and significant findings on the role of miRNAs in cancer cell drug resistance. In particular, we focus on specific miRNA mechanisms of action that in various steps lead from drug cell sensitivity to drug cell resistance. We also provide evidence on how miRNA profiling may unveil relevant predictive biomarkers for therapy outcomes.
化疗耐药是癌症治疗中的主要问题之一。癌细胞通过多种不同的分子机制获得对特定治疗的耐药性，例如药物摄取、药物代谢和药物靶点的改变。有多项证据表明，微小RNA（miRNA）参与了不同肿瘤类型和不同治疗方式下癌细胞的药物敏感性。在本综述中，我们概述了miRNA在癌细胞耐药性方面的最新重要研究发现。特别是，我们关注miRNA在从药物细胞敏感性到药物细胞耐药性的各个步骤中的具体作用机制。我们还提供了证据，证明miRNA谱分析如何揭示与治疗结果相关的预测性生物标志物。
